Lilly Eli & Co Stock Price, News & Analysis

Eli Lilly and Company (NYSE: LLY) will participate in the fourth annual Evercore ISI HealthCONx Conference on Nov. 30, 2021. Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific and medical officer, will engage in a fireside chat at 12:10 p.m. Eastern time. A live audio webcast of the event will be available on Lilly's Investor website, with a replay accessible for 90 days post-event.

Lilly, a global healthcare leader, focuses on creating impactful medicines and enhancing disease management.

The FDA has accepted a supplemental New Drug Application for Jardiance (empagliflozin) 10 mg, granting it Priority Review. This application aims to establish Jardiance as a treatment for reducing the risk of cardiovascular death and hospitalization for heart failure in adults, regardless of left ventricular ejection fraction (LVEF). In the EMPEROR-Preserved trial, Jardiance showed a 21% relative risk reduction for the primary endpoint versus placebo. If approved, it would be the first treatment proven to improve outcomes in patients with preserved ejection fraction heart failure.

Eli Lilly and Company (NYSE: LLY) has announced the winners of the inaugural Leonard Award, celebrating the 100th anniversary of insulin's discovery. Each of the five awardees will receive $20,000, totaling $100,000 in donations to Life for a Child, which aids children with type 1 diabetes in low-resource settings. The winners were chosen from over 70 submissions evaluated by an esteemed panel based on impact and feasibility. This initiative highlights Lilly's ongoing commitment to diabetes care and community support.

Eli Lilly and Company (NYSE: LLY) will participate in the Wolfe Research Virtual Healthcare Conference on Nov. 18, 2021. Key executives, including Jacob Van Naarden, CEO of Loxo Oncology, will engage in a fireside chat at 10:30 a.m. Eastern time. Investors can access the event via a live audio webcast on the company's investor website, with a replay available for 90 days afterward. Lilly is committed to improving global health through innovative medicines and community support, continuing a century-old mission.

OLUMIANT (baricitinib) continues to demonstrate a consistent safety profile in a long-term analysis involving 3,770 rheumatoid arthritis (RA) patients across 14,744 patient years of exposure. The overall incidence rate of adverse events stood at 22.6 per 100 patient years, with serious adverse events at 7.4. Safety results will be presented by Eli Lilly and Company and Incyte at ACR Convergence 2021. A real-world study in Japan involving 3,445 RA patients also showed no new safety signals, reinforcing OLUMIANT's safety over 24 weeks. OLUMIANT is approved in over 75 countries for RA treatment.

The EMPEROR-Preserved phase III trial revealed that Jardiance (empagliflozin) significantly reduces the risk of cardiovascular death or hospitalization for heart failure and slows kidney function decline in adults with heart failure and left ventricular ejection fraction (LVEF) over 40%. Presented at the American Society of Nephrology Kidney Week 2021, findings showed consistent benefits regardless of chronic kidney disease (CKD) status. The trial included nearly 6,000 adults, with results highlighting the potential for Jardiance as a viable treatment option. Fast Track and Breakthrough Therapy designations have been granted for its cardiovascular applications.

Loxo Oncology at Lilly announced the upcoming presentation of data from the pirtobrutinib development program at the ASH Annual Meeting, scheduled for December 11-14, 2021. Pirtobrutinib is a reversible BTK inhibitor currently undergoing clinical trials for chronic lymphocytic leukemia and mantle cell lymphoma. Oral presentations will feature updated results from the Phase 1/2 BRUIN trial, focusing on patients previously treated for these conditions. The trials highlight the drug's potential efficacy and innovative mechanism against acquired resistance.

Eli Lilly announced an agreement with the U.S. government to supply 614,000 doses of bamlanivimab with etesevimab, a COVID-19 treatment, for $1.29 billion. The deal is expected to add approximately $840 million in revenue and 25 cents per share to Lilly's 2021 earnings. The doses will be delivered by January 31, 2022, with a minimum of 400,000 by December 31, 2021. Bamlanivimab and etesevimab are authorized under Emergency Use Authorization for specific COVID-19 cases but are not FDA-approved. The supply is supported by federal funds under a BARDA contract.

Eli Lilly and Company (NYSE: LLY) will participate in Bernstein's Second Annual Operational Decisions Conference on Thursday, Nov. 4, 2021. Key executives including Jake Van Naarden, Mark Mintun, and Jamie Croaning will engage in a virtual fireside chat at 12:30 p.m. Eastern time. Investors can access a live audio webcast via Lilly's Investor website, with a replay available for 90 days. Lilly aims to improve global health care through innovative medicines and community support, continuing a mission established over a century ago. For more details, visit www.lilly.com.